GLP-1 Agonist Prescriptions Rise by Nearly 600% Among Youth From 2020 to 2023
GLP-1 agonists were most frequently prescribed to adolescents and adults by endocrinologists and nurse practitioners, respectively. Dispensing of glucagon-like peptide-1…
Tag: Wegovy
Study: Semaglutide Lowered Chronic Kidney Disease–Related Risks
Chronic kidney disease, most commonly caused by diabetes and high blood pressure, puts more than half a billion people globally at high…
Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024
Novo Nordisk announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of…
Ozempic’s Hidden Challenges: A Personal Journey of Weight Loss and Self-Discovery
Author Johann Hari shares his experience with Ozempic, revealing both the benefits and unexpected psychological toll of the popular weight-loss…
Rethinking Exercise with GLP-1 Medications: Beyond Weight Loss
In the era of revolutionary type 2 diabetes medications like Ozempic, Mounjaro, and Trulicity, many patients are experiencing unprecedented weight…
Title: The Paradox of GLP-1 Receptor Agonists: Increased Osteoarthritis Progression in Diabetic Patients
A recent study published in The Journal of Arthroplasty has revealed unexpected findings regarding the effects of glucagon-like peptide-1 receptor…
GLP-1 Drugs Like Ozempic Set to Shake Up the Snack Food Industry
The snack food industry is bracing for a seismic shift as the popularity of GLP-1 medications, such as Ozempic and…
GLP-1 Drugs and Weight Loss Surgeries Demonstrate Comparable Reductions in Obesity-Related Cancers
A groundbreaking study has revealed that the use of GLP-1 receptor agonist medications, such as Ozempic and Wegovy, may be…
Diabesitology: A Call for Novel Clinical Trial Designs in the Golden Era of GLP-1 Axis Medications
As we enter what many experts are calling the “golden era” of GLP-1 axis medications, a new field of study—”diabesitology”—is…
Boehringer and Zealand Intensify the Race for a Potent GLP-1/Amylin Combo Therapy
The quest for increasingly effective and comprehensive obesity treatments has intensified, with pharmaceutical giants Boehringer Ingelheim and Zealand Pharma joining…
